Mode
Text Size
Log in / Sign up
N/A N=53 Randomized Single-blind Treatment

Increasing Caregiver Engagement in Juvenile Drug Courts

Substance Abuse

Enrolled (actual)
53
Serious AEs
11.3%
Results posted
Dec 2025
Primary outcome: Primary: Number of Participants With Positive Urine Drug Screens at 5 Months Post-baseline — 18; 13 participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Caregiver Contingency Management + Usual Drug Court Treatment (Behavioral); Usual Drug Court Treatment (Behavioral)
Age
Pediatric, Adult, Older Adult · 13+ yrs
Sex
All
Sponsor
Medical University of South Carolina
Primary completion
Dec 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Positive Urine Drug Screens at 5 Months Post-baseline
18; 13
PRIMARY
Frequency of Substance Use and Substance-related Problems Self-reported by Youth on the Global Appraisal of Individual Needs.
2.56; 8.03; 4.26; 12.69; 0.63; 2.85
SECONDARY
Changes From Baseline to 18 Months Post-baseline in Youth Arrests, Charges, and Convictions.
SECONDARY
Changes From Baseline to 18 Months Post-baseline in Youth Delinquent Behaviors (Measured at 0, 3, 5, 6, 9, 12, and 18 Months).
SECONDARY
Changes From Baseline to 18 Months Post-baseline in Caregiver Reports on Youth Internalizing Symptoms and Externalizing Behaviors (Measured at 0, 1, 2, 3, 4, 5, 6, 9, 12, and 18 Months).
SECONDARY
Changes From Baseline to 18 Months Post-baseline in Youth Reports on Youth Internalizing Symptoms and Externalizing Behaviors (Measured at 0, 1, 2, 3, 4, 5, 6, 9, 12, and 18 Months).
SECONDARY
Changes From Baseline to Post-treatment in Caregiver Substance Use Problems.
SECONDARY
Changes From Baseline to Post-treatment in Caregiver Depressive Symptoms.
SECONDARY
Changes From Baseline to Post-treatment in Therapist-Family Working Alliance (Measured at 1, 2, 3, and 4 Months, as Well as Post-treatment).
SECONDARY
Changes From Baseline to Post-treatment in Caregiver Treatment Attendance and Activity Completion (Measured at 1, 2, 3, and 4 Months, as Well as Post-treatment).
SECONDARY
Changes From Baseline to the End of JDC Involvement in Caregiver Attendance at JDC Sessions.
SECONDARY
Rates of Treatment Completion.
SECONDARY
Levels of Satisfaction With Treatment and JDC.
SECONDARY
Changes From Baseline to Post-treatment in Caregiver Perceptions of Incentive Programs.
SECONDARY
Changes From Baseline to 36 Months Post-baseline in Therapist and JDC Personnel Perceptions of Incentive Programs (Measured at 0, 12, 24, and 36 Months).
SECONDARY
Reports at Post-treatment on Youth and Caregiver Attitudes Toward Incentive Programs.
SECONDARY
Changes From Baseline to 36 Months Post-baseline in Therapist and JDC Personnel Attitudes Toward Incentive Programs (Measured at 0, 12, 24, and 36 Months).

Summary

The purpose of this study is to test a prize-based contingency management intervention for increasing caregiver engagement in juvenile drug court and adolescent drug treatment, and for achieving the ultimate outcomes of reduced substance use and delinquent behavior among drug court-involved youth.

Eligibility Criteria

Inclusion Criteria for youth:

  • Involved in juvenile drug court
  • Aged 13-17 years
  • Youth is willing to participate
  • At least one caregiver is willing to participate in the youth's treatment
  • Fluent in English or Spanish

Exclusion Criteria for youth:

  • Diagnosed with intellectual disability or autism spectrum disorder

Inclusion Criteria for caregivers:

  • Caregiver of youth involved in juvenile drug court
  • Caregiver is willing to participate
  • Fluent in English or Spanish

Exclusion Criteria for caregivers:

  • Diagnosed with intellectual disability or autism spectrum disorder

Inclusion Criteria for therapists:

  • Providing substance abuse treatment to a youth in juvenile drug court

Exclusion Criteria for therapists:

  • None

Inclusion Criteria for Juvenile Drug Court Personnel:

  • Personnel working in juvenile drug court

Exclusion Criteria for Juvenile Drug Court Personnel:

  • None
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03051997). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search